All In Biotech

Drug Trial Radar · NCT06309953

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

99

Actual

Start

Feb 28, 2024

Primary completion

Jun 17, 2024

Study completion Jun 17, 2024

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Conditions

  • Dry Eye

Interventions

  • MieboDrug

    Miebo® (perfluorohexyloctane ophthalmic solution) Dosage: one drop of MIEBO four times daily into each eye Dosage form: Ophthalmic solution: 100% perfluorohexyloctane. Frequency: 4 times daily for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline (CFB) in Dry Eye Symptom Severity at Visit 3Time frame: Change from baseline in VAS at Visit 3 (Day 7 ± 1 day)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Site 207

    Birmingham, Alabama

  • Site 205

    Petaluma, California

  • Site 203

    Pittsburg, Kansas

  • Site 204

    Stillwater, Minnesota

  • Site 202

    Kansas City, Missouri

  • Site 201

    Brecksville, Ohio

  • Site 206

    Westlake, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.